(Q77349606)

English

Dose-intensive first-line chemotherapy with epirubicin and continuous infusion ifosfamide in adult patients with advanced soft tissue sarcomas: a phase II study

scientific article published on 01 January 1999

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10211090%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

Dose-intensive first-line chemotherapy with epirubicin and continuous infusion ifosfamide in adult patients with advanced soft tissue sarcomas: a phase II study (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10211090%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

1 reference

based on heuristic

inferred from title

author name string

R Palumbo

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10211090%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

C Neumaier

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10211090%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

M Cosso

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10211090%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

G Bertero

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10211090%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

P Raffo

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10211090%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

N Spadini

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10211090%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

S Valente

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10211090%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

G Villani

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10211090%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

M Pastorino

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10211090%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

S Toma

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10211090%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

publication date

1 January 1999

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10211090%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

European Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10211090%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

35

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10211090%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10211090%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

66-72

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10211090%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

Doxorubicin (or epidoxorubicin) combined with ifosfamide in the treatment of adult advanced soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900293-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900293-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900293-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900293-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose response evaluation of adriamycin in human neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900293-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyvadic in advanced soft tissue sarcoma: A randomized study comparing two schedules: A study of the EORTC soft tissue and bone sarcoma group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900293-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900293-7

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose ifosfamide with mesna uroprotection: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900293-7

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900293-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidoxorubicin plus ifosfamide in advanced and/or metastatic soft-tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900293-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Ambulatory 4-day continuous-infusion schedule of high-dose ifosfamide with mesna uroprotection and granulocyte colony-stimulating factor in advanced solid tumours: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900293-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900293-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Feasibility and compliance of epirubicin plus ambulatory continuous infusion ifosfamide at escalating doses in advanced soft tissue sarcomas: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900293-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900293-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900293-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcom

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900293-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Increasing 4'-epidoxorubicin and fixed ifosfamide doses plus granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900293-7

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900293-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised study of high-dose epirubicin versus high-dose epirubicin-cisplatin chemotherapy for advanced soft tissue sarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900293-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Lung metastasectomy in patients with soft tissue sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900293-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Needed: qualitative improvement in antisarcoma therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900293-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Soft tissue sarcoma—messages from completed randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900293-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The outcome of advanced soft tissue sarcoma patients with complete tumour regression after either chemotherapy alone or chemotherapy plus surgery. The Scandinavian Sarcoma Group experience

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900293-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0959-8049(98)00293-7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10211090%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10211090%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q77349606&oldid=1642369394"